Malaria Journal

Table 2 Incidence of solicited local adverse events per vaccine type per dose

From: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

		First dose						Second dose						Third dose
		15 μg MSP3		30 μg MSP3		Engerix B		15 μg MSP3		30 μg MSP3		Engerix B		15 μg MSP3		30 μg MSP3		Engerix B
		N = 15		N = 15		N = 15		N = 15		N = 15		N = 15		N = 15		N = 15		N = 15
Symptom	Intensity	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any	Overall	8	53	10	67	7	47	12	80	6	40	6	40	9	60	12	80	9	60
	Grade 3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pain	Overall	3	20	2	13	1	6.7	1	6.7	1	6.7	1	6.7	0	0	1	6.7	2	13
	Grade 3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Swelling	Overall	3	20	7	47	5	33	4	27	1	6.7	1	6.7	3	20	2	13	3	20
	Grade 3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Erythema	Overall	0	0	2	13	1	6.7	1	6.7	1	6.7	1	6.7	1	6.7	0	0	2	13
	Grade 3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Induration	Overall	8	53	10	67	6	40	12	80	7	47	6	40	8	53	12	80	8	53
	Grade 3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pruritus	Overall	0	0	0	0	0	0	0	0	0	0	1	6.7	0	0	0	0	0	0
	Grade 3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Back to article page

ISSN: 1475-2875

Contact us

Submission enquiries: journalsubmissions@springernature.com